Flare Therapeutics to Present at the Bank of America Securities 2022 Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Flare Therapeutics, a [privately-held] biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced that Daphne Karydas, chief operating officer and chief financial officer will present at the upcoming Bank of America Securities 2022 Healthcare Conference on Thursday, May 12th at 10:00 a.m. PT in Las Vegas, Nevada.

About Flare Therapeutics:

Flare Therapeutics is a biotechnology company opening a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets for transcription factor regulation to address mutations that cause disease. Our drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology and inflammation. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors and Eventide Asset Management. For more information, please visit www.flaretx.com.

We invite you to follow us on LinkedIn and @Flaretx.

Investors
Sarah McCabe
Stern Investor Relations, Inc.
Sarah.mccabe@sternir.com

Media
Michelle Thaler
Michelle Thaler PR, LLC
516-225-4313
MichelleThalerPR@gmail.com